Bortezomib Triplet Improves Outcomes in Newly Diagnosed Multiple Myeloma

Adding bortezomib to lenalidomide and dexamethasone improved progression-free and overall survival in patients with newly diagnosed multiple myeloma who were not planned for immediate stem-cell transplant.

Source: CancerNetwork - January 18, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news